内舒拿与雷诺考特治疗变应性鼻炎疗效比较

目的对比内舒拿(糠酸莫米松)鼻喷剂和雷诺考特（布地奈德）鼻喷剂治疗变应性鼻炎的临床疗效。方法将临床确诊为常年性变应性鼻炎160例患者随机分为两组:内舒拿组80例,雷诺考特组80例。内舒拿鼻喷剂每次每侧鼻孔2喷(50μg／喷)，1次/d(总量200μg)，于早晨喷入。雷诺考特鼻喷剂每侧鼻腔喷两喷（64μg／喷），1次/d(总量256μg) ，早晨喷入。两组疗程均为4周。观察两种药物的临床疗效及不良反应。结果内舒拿组和雷诺考特组治疗前后均自身对比，治疗前后症状和体征评分差异均有统计学意义（P＜0．05）。总有效率：内舒拿组为97.5％，雷诺考特组为92.5％，两组差异无统计学意义（P＞0．05）。两组均无严重的不良反应。结论两种药物治疗变应性鼻炎均有良好疗效，具有高效、安全、方便、依从性好、不良反应少等优点，均可单独用于治疗变应性鼻炎，改善患者生活质量。

A contrast of the therapeutic effects of Nasonex and Rhinocort in the treatment of allergic rhinitis

To investigate the therapeutic effects of Nasonex Nasal Spray(momestasone furoate) and Rhinocort Nasal Spray(budesonide) on allergic rhinitis(AR). Methods160 patients with AR were randomly divided into two groups: the Nasonex group (n=80) were treated with Nasonex once daily (total 200μg) and the Rhinocort group (n=80) were treated with Rhinocort once daily (total 256μg) for 4 weeks. Clinical effects and adverse drug reactions were observed. ResultsThere were statistical differences between the pre-and post-treatment groups (both P＜0.05). The total effective rate was 97.5% in the Nasonex group and 92.5% in the Rhinocort group, however, there was no statistical difference between the two groups (P＞0.05). No severe adverse drug reaction was found in either group. ConclusionsBoth medicines have good therapeutic effects on allergic rhinitis. Either one can be used for allergic rhinitis alone and achieve ideal therapeutic efficacies.